• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

The Potential Role of PCSK9 Inhibitors for Patients With Hyperlipidemia

Video

John A. Johnson, MD, MBA: The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors are fairly new medications that have become available, and, again, as we’ve mentioned earlier, the statins are also available.

We’ve seen that even with maximum statin therapy with drugs such as Crestor or Lipitor (at the maximum dose), it’s still a challenge for some clinicians to get their hyperlipidemic patients to an LDL (low-density lipoprotein) below goal. Again, the goal depends on the risks the patient has. But, in general, an LDL below 100 would be acceptable for a diabetic or below 70 for a diabetic with heart disease.

So, it’s oftentimes difficult to push the statin to a high enough dose without causing some of the safety or tolerability concerns [for] the patient. You may have to move toward a combination therapy, and newer agents are becoming available. At the health plan [level], we make those medications available when we’ve seen documentation that other medications are less effective.


Related Videos
1 KOL is featured in this series.
Screenshot of Susan Wescott, RPh, MBA
5 KOLs are featured in this series.
4 KOLs are featured in this series
5 KOLs are featured in this series.
5 KOLs are featured in this series.
4 KOLs are featured in this series
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Screenshot of Stephanie Hsia, PharmD
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.